

## RESEARCH ARTICLE

# Genetic ablation of serotonin receptor 2B improves aortic valve hemodynamics of *Notch1* heterozygous mice in a high-cholesterol diet model

J. Ethan Joll II, Cynthia R. Clark, Christine S. Peters, Michael A. Raddatz , Matthew R. Bersi , W. David Merryman \*

Department of Biomedical Engineering, Vanderbilt University, Nashville, TN, United States of America

\* [david.merryman@vanderbilt.edu](mailto:david.merryman@vanderbilt.edu)



## OPEN ACCESS

**Citation:** Joll JE, II, Clark CR, Peters CS, Raddatz MA, Bersi MR, Merryman WD (2020) Genetic ablation of serotonin receptor 2B improves aortic valve hemodynamics of *Notch1* heterozygous mice in a high-cholesterol diet model. PLoS ONE 15(11): e0238407. <https://doi.org/10.1371/journal.pone.0238407>

**Editor:** Elena Aikawa, Brigham and Women's Hospital, Harvard Medical School, UNITED STATES

**Received:** August 12, 2020

**Accepted:** November 9, 2020

**Published:** November 25, 2020

**Copyright:** © 2020 Joll II et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** All relevant data are within the manuscript and its [Supporting Information](#) files.

**Funding:** This work was supported by the following NIH grants: F31-HL151115 (JEJ II), F30-HL147464 (MAR), K99-HL146951 (MRB), R01-HL115103 (WDM), R35-HL135790 (WDM). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

## Abstract

Calcific aortic valve disease (CAVD) is a deadly disease that is rising in prevalence due to population aging. While the disease is complex and poorly understood, one well-documented driver of valvulopathy is serotonin agonism. Both serotonin overexpression, as seen with carcinoid tumors and drug-related agonism, such as with Fenfluramine use, are linked with various diseases of the valves. Thus, the objective of this study was to determine if genetic ablation or pharmacological antagonism of the 5-HT<sub>2B</sub> serotonin receptor (gene: *Htr2b*) could improve the hemodynamic and histological progression of calcific aortic valve disease. *Htr2b* mutant mice were crossed with *Notch1*<sup>+/-</sup> mice, an established small animal model of CAVD, to determine if genetic ablation affects CAVD progression. To assess the effect of pharmacological inhibition on CAVD progression, *Notch1*<sup>+/-</sup> mice were treated with the 5-HT<sub>2B</sub> receptor antagonist SB204741. Mice were analyzed using echocardiography, histology, immunofluorescence, and real-time quantitative polymerase chain reaction. *Htr2b* mutant mice showed lower aortic valve peak velocity and mean pressure gradient—classical hemodynamic indicators of aortic valve stenosis—without concurrent left ventricle change. 5-HT<sub>2B</sub> receptor antagonism, however, did not affect hemodynamic progression. Leaflet thickness, collagen density, and CAVD-associated transcriptional markers were not significantly different in any group. This study reveals that genetic ablation of *Htr2b* attenuates hemodynamic development of CAVD in the *Notch1*<sup>+/-</sup> mice, but pharmacological antagonism may require high doses or long-term treatment to slow progression.

## Introduction

The aortic valve (AV) controls unidirectional oxygenated blood flow from the left ventricle into the systemic circulation. Comprised of a compliant tri-leaflet structure, this valve permits unimpeded blood flow during systole yet forms a strong coaptation to prevent regurgitation during diastole. Calcific aortic valve disease (CAVD) is characterized by the accumulation of

**Competing interests:** The authors have declared that no competing interests exist.

stiff fibrotic and/or calcific deposits on the leaflet cusps which can impede blood flow, causing aortic stenosis (AS) and leading to heart failure and death if left untreated [1]. AS is one of the deadliest cardiovascular diseases and is becoming an increasing public health concern in aging populations [1]. The disease is estimated to be present in 1.7% of patients over the age of 65 and 3.4% over the age of 75 [2, 3]. Severe AS is particularly deadly, carrying a two-year survival rate as low as 22% in those with the most highly impeded blood flow [4]. Estimates from 2017 indicate AS accounts for approximately 17,000 deaths in North America per year [5].

The molecular pathophysiology of CAVD is poorly understood. Originally thought to be a passive, degenerative process, research in recent decades has revealed a complex, actively regulated biological process leading to disease [6]. Roles have been defined for pathological activation of resident cells including valvular endothelial cells (VECs) and valvular interstitial cells (VICs). VICs broadly contribute to CAVD through two mechanisms: dystrophic and osteogenic calcification. Dystrophic calcification is characterized by a shifting of VICs from a quiescent phenotype to a synthetic and contractile phenotype with upregulation of alpha smooth muscle actin ( $\alpha$ SMA) and cadherin-11 [7]. In osteogenic calcification, VICs can also transition to an osteoblast-like phenotype characterized by upregulation of Runt-related transcription factor 2 (Runx2), alkaline phosphatase, and ectopic bone formation [7, 8].

There are currently no pharmaceutical options for slowing or treating CAVD. Surgical and transcatheter AV replacements can restore functionality; however, those suffering from late stage cardiovascular disease also often carry higher risk for complications from surgical interventions and many are left untreated [9]. Therefore, a pharmaceutical alternative would be of great benefit.

One of the earliest and best-documented mechanisms driving diseases of the heart valves is the serotonin signaling pathway. Endocrine diseases leading to overexpression of serotonin, such as carcinoid tumors, have been linked with multiple valvulopathies, and serotonin receptor agonists such as Fenfluramine (an anti-obesity drug marketed in the 1990s) have been clearly shown to exacerbate valve disease [10, 11]. Fenfluramine was found to specifically activate 5-HT<sub>2B</sub>, the serotonin receptor 2B subtype [12, 13]. Signaling through 5-HT<sub>2B</sub> has been implicated in several small animal models of cardiovascular disease. Prior work has shown that activating the 5-HT<sub>2B</sub> receptor via selective agonism can lead to valve pathology in a rat model [14]. Additionally, 5-HT<sub>2B</sub> ablation in mice causes decreased ventricular mass and diminished systolic function [15]. 5-HT<sub>2B</sub> signaling has also been shown to be involved in isoproterenol and angiotensin II induced cardiac hypertrophy, primarily affecting myocardial fibroblasts [16, 17]. Studies in dogs show increased 5-HT<sub>2B</sub> gene expression in symptomatic myxomatous mitral valve disease and protein co-localizes with  $\alpha$ SMA positive myofibroblasts [18]. Recent studies indicate 5-HT<sub>2B</sub> activation induces early hallmarks of pathological mitral valve remodeling which is attenuated by genetic knockout and receptor antagonism. Interestingly the phenomenon may be mediated by bone-marrow derived endothelial progenitor cells [19]. Our laboratory has previously shown that antagonism of 5-HT<sub>2B</sub> can reduce AV myofibroblast activation by repressing non-canonical TGF- $\beta$  signaling *in vitro* [20], indicating that 5-HT<sub>2B</sub> may be a therapeutic target for CAVD.

These clinical and basic research findings led us to hypothesize that 5-HT<sub>2B</sub> may be a novel target for pharmacological treatment of CAVD. Therefore, we evaluated the impact of both genetic and pharmacological ablation of 5-HT<sub>2B</sub> in the well-established *Notch1*<sup>+/-</sup> mouse model of CAVD, based on the heritable form in patients with *NOTCH1* mutations [21–25]. Briefly, we found that genetic ablation mitigated CAVD phenotypes, while pharmacological targeting was not efficacious.

## Materials and methods

### Mouse models

All animal procedures were approved and carried out in accordance with relevant guidelines and regulations established by the Institutional Animal Care and Use Committee at Vanderbilt University. Briefly, *Notch1*<sup>+/-</sup> and *Htr2b*<sup>-/-</sup> mice were crossed to create *Notch1*; *Htr2b* double mutant animals [26, 27]. In a separate cohort, Alzet minipumps (model 1004) delivering either the high-affinity 5-HT<sub>2B</sub> antagonist SB204741 (Tocris Biosciences; 1 mg kg<sup>-1</sup>d<sup>-1</sup>) or vehicle (50% dimethyl sulfoxide [Sigma-Aldrich] and polyethylene glycol-400 [Fisher Chemical]) were implanted subcutaneously in *Notch1*<sup>+/-</sup> mice at 4 months of age (Fig 1). SB204741 is a well-validated and specific 5-HT<sub>2B</sub> receptor antagonist commonly used in pharmacological studies targeting this ligand [28, 29]. SB204741 dosing varies widely across the literature, but we use 1 mg kg<sup>-1</sup>d<sup>-1</sup> to allow for longer time course administration with good results [30].

All mice were fed a 1% cholesterol Western diet (TestDiet 5TJT) for a total of 3.5 months beginning at 2.5 months of age. Food and water were provided ad libitum. Mice were sacrificed at 6 months of age using carbon dioxide inhalation followed by cervical dislocation before harvesting biological samples for processing and analysis.

### Echocardiography


*In vivo* transthoracic echocardiography was performed by the Vanderbilt Cardiovascular Physiology Core using a Vevo 2100 small animal imaging system. Mice were lightly anesthetized (average heart rate of 465 bpm) using isoflurane inhalation and placed supine on a heated stage in order to obtain a clear image of the aortic root. AV jet velocity profiles were estimated by aortic pulsed-wave Doppler imaging. A custom MATLAB script was implemented to determine the maximum systolic velocity and mean pressure gradient [31]. Three images were analyzed per mouse yielding a total of ~100 cardiac cycles that were quantified and averaged to reliably quantify AV hemodynamic characteristics.

Concurrently, parasternal short-axis M-mode imaging was performed to study the effects on cardiac function and left ventricular performance. Systolic and diastolic measurements were performed to obtain estimates of ejection fraction and ventricular mass. For each mouse, ~9 cardiac cycles were averaged to obtain representative cardiac function metrics. Electrocardiographic measurements were acquired while imaging to allow for cardiac cycle-based gating of measurements using R wave peaks.

### Histological and immunofluorescence staining

Mice were euthanized at 6 months of age and aortic roots were immediately dissected and either flash frozen or embedded in optimal cutting temperature (OCT) compound. Embedded samples were stored at -80° C until they were cut at 10 μm serial sections in a -20° C cryostat. For all tissue analysis, 3–5 sections were sampled across separate regions of the valve to produce a representative summary of valve characteristics.

To assess microstructural differences between AVs from different groups Masson's Trichrome staining (Sigma-Aldrich) was used according to manufacturer instructions. Briefly, nuclei (black) were highlighted with Weigert's iron hematoxylin, muscle and cytoplasm (red) with Beibrich scarlet-acid fuchsin, and collagen (blue) with aniline blue post-phosphotungstic and phosphomolybdic acid wash; slides were treated with Bouin's solution to improve color intensity. Slides were rinsed in acetic acid, dehydrated in progressively concentrated ethyl alcohol baths, cleared with xylene, and mounted in organic mounting media. Brightfield images were taken using the Nikon Eclipse E800 microscope under a 4X magnification objective.



**Fig 1. The effects of genetic ablation and pharmacological inhibition of 5-HT<sub>2B</sub> on CAVD development were studied using a high-cholesterol diet *Notch1*<sup>+/-</sup> mouse model.** A. Mutant mice were aged to six months on high-cholesterol diet and doppler and M-mode echocardiography was utilized to determine hemodynamic phenotype in the valve and left ventricle. B. *Notch1*<sup>+/-</sup> mice were aged to six months with SB204741 infusion between 4 and 6 months. Doppler and M-mode echocardiography were performed at 4 and 6 months. All mice were sacrificed at 6 months. Black bar = 1 month.

<https://doi.org/10.1371/journal.pone.0238407.g001>

To assess osteogenic calcification, Alizarin Red S staining was performed (Sigma-Aldrich). Fresh frozen sections were washed with 1X phosphate buffered saline and deionized water. Sections were then incubated for one hour in 14 mM Alizarin Red S solution. Sections were rinsed in water, then dipped 20 times each in sequential baths of acetone, 1:1 acetone/xylene solution, and xylene. Slides were then mounted in organic mounting media. Brightfield images were taken using a Nikon Eclipse E800 microscope under a 4x magnification objective.

To assess the level of myofibroblast activation or osteoblast-like phenotype induction between groups, sections were stained for  $\alpha$ SMA and Runx2. The downstream effector of 5-HT<sub>2B</sub> activation, phospho-p44/42 mitogen-activated protein kinase (phospho-ERK1/2) was also stained. Sections were fixed and permeabilized in 4% paraformaldehyde/0.1% Triton-X solution. Non-specific binding was reduced by incubating in 10% bovine serum albumin in 1X phosphate buffered saline for one hour. Sections were then incubated in rabbit polyclonal anti- $\alpha$ SMA, rabbit monoclonal anti-Runx2, or rabbit monoclonal anti-phospho-ERK1/2 at 4° C overnight (Abcam ab5694, 1:100; Cell Signaling Technology 12556, 1:100; Cell Signaling Technology 4370, 1:200). Slides were thoroughly washed the next day then incubated in goat anti-rabbit IgG Alexa Fluor 647 secondary antibody for 1 hour at room temperature (ThermoFisher A-21245, 1:1000). Slides were thoroughly washed then mounted with ProLong Gold Antifade with DAPI (Cell Signaling Technology 8961), sealed, and stored at -20° C. Fluorescent images were taken using an Olympus BX53 microscope equipped with a high resolution Qimaging Retiga 3000 camera under a 20X magnification objective.

### Quantitative image analysis

Custom MATLAB scripts for quantitative image analysis were implemented to identify changes in leaflet composition and microstructure. Images from different samples were acquired with the same set of exposures and background levels in order to allow for quantification and comparison of image intensities.

For Masson's Trichrome stained images, colorimetric segmentation in an HSL color space was performed in order to identify the area fractions of collagen (blue; H = 150°-250°, S = 0.1-1.0, L = 0.1-0.93) and cytoplasm/myocardium (red; H = 250°-25°, S = 0.1-1.0, L = 0.1-0.93) in each field of view [32]. Area fractions for each constituent were computed as the ratio of positive pixels to non-background pixels within the specified AV leaflet area.

For immunofluorescence images, co-staining of DAPI and either  $\alpha$ SMA or Runx2 was imaged in separate fluorescent channels at the same location. Total valve leaflet area was estimated from DAPI images based on a manually defined leaflet boundary. Segmentation of individual nuclei was also performed [33]. Briefly, DAPI positive pixels were separated from the image background based on a fuzzy c-means segmentation, and individual nuclear boundaries were estimated using a modified watershed transform. Contacting nuclei were identified and split based on a concave object separation algorithm [34].  $\alpha$ SMA area fractions were then computed as the ratio of positive pixels to total leaflet pixels based on the defined leaflet boundary. Runx2 expression was defined based on the ratio of positive pixels to total pixels within each identified nuclear boundary where Runx2 positive nuclei were defined as having greater than 50% Runx2 stain coverage. Positive nuclei counts were normalized to the number of total nuclei.  $\alpha$ SMA and Runx2 positive pixels were defined as those with intensity values greater than the median stain intensity value within the leaflet boundary.

### Real-time quantitative polymerase chain reaction

Flash frozen aortic roots containing intact AVs were suspended in Trizol Reagent (ThermoFisher 15596026) and homogenized using a bead homogenizer (BioSpec Products). RNA was isolated using phenol-chloroform extraction as described based on manufacturer protocols. RNA purity and concentration were measured using the NanoDrop UV Spectrophotometer (ThermoFisher ND-ONE-W). cDNA was generated with the SuperScript IV First-Strand Synthesis System (ThermoFisher 18091150) based on manufacturer protocols. SYBR Green PCR Master Mix (ThermoFisher 4309155) was used to facilitate detection during target amplification. The CFX96 Real-Time PCR Detection System (Bio-Rad) was used to monitor fluorescent

**Table 1. Primer nucleotide sequences used for RT-qPCR.**

Target	Forward primer	Reverse primer
<i>Acta2</i>	tctggacgtacaactggattg	ggcagtagtcacgaaggaatag
<i>Actb</i>	caagcaggagtacgatgagtc	aacgcagctcagtaacagtc
<i>Cdh11</i>	acaccatgagaagggaag	accggagtcaatgtcagaatg
<i>Col1a1</i>	cataaagggtcacgtggct	ttgagtcctgtctttgccag
<i>Ccn2</i>	ctccaccgagttaccaatg	gcctgtatgtcttcacactg
<i>Gapdh</i>	atgacaatgaatacggctacag	tctcttgctcagtgctccttg

<https://doi.org/10.1371/journal.pone.0238407.t001>

intensity during amplification. cDNA was initially denatured at 95° C for four minutes, then cycled 40 times through the following cycle: 10 sec 95° C, 10 sec at 55° C anneal, plate read. A melt curve was generated after cycling by increasing temperature from 65 to 95° C at 0.5° C for 5 sec and performing a plate read at each increment. Bio-Rad CFX Manager 3.1 software was used to automatically calculate the cycle quantification value at which samples amplified at a high enough value to be detected. Relative changes in transcript expression were determined by normalizing to the geometric mean of two housekeeping genes: *Gapdh* and *Actb*. Statistics were performed on untransformed  $\Delta C_t$  values. All primers are included below (Table 1).

Primers were designed using the Integrated DNA Technologies PrimerQuest tool. Primers were designed to span one exon and with a 3' bias. Product sizes of less than 300 were selected. Sequences were verified using NCBI Primer-BLAST to fully match the target transcript and have no significant off target interactions.


### Statistical analysis

Data are presented as mean +/- standard error of the mean (SEM), unless otherwise noted. All data sets were tested for normality using the D'Agostino-Pearson omnibus normality test. Data sets passing the normality test were analyzed using parametric tests: Student's *t*-test for 2 group comparison and one-way analysis of variance (ANOVA) for 3 or more groups. Small groups (sample size less than 7) or groups with non-normal distribution were analyzed using non-parametric tests: Mann-Whitney U test for 2 group comparison and Kruskal-Wallis one-way analysis of variance for 3 or more groups. For analyzing absolute change from four to six months in the drug study, the one-sample *t* test or Wilcoxon signed-rank test was used for parametric and non-parametric data, respectively. To account for multiple comparisons, statistical significance was corrected in post-hoc tests using Tukey or Dunn's correction for parametric and non-parametric tests, respectively. For all tests, a p-value of 0.05 was considered statistically significant. Data storage and statistical analysis was performed using Microsoft Excel, MATLAB r2019a, and GraphPad Prism 8.4.1.

## Results

### Genetic ablation of *Htr2b* rescues hemodynamic metrics of aortic valve disease

At 6 months, peak velocity is 15–20% higher than the average peak velocity found in the *LDLr<sup>-/-</sup>/ApoB<sup>100/100</sup>/IGF-II<sup>+/-</sup>* mutant model of CAVD [35]. Using a previously reported threshold of 1320 mm/s [35], incidence of severe CAVD decreased with ablation of *Htr2b* gene (S1 Fig). Ablation of *Htr2b* from *Notch1<sup>+/-</sup>* mice decreases the average peak velocity during the cardiac cycle with a corresponding decrease in mean pressure gradient across the AV, relative to *Notch1<sup>+/-</sup>;Htr2b<sup>+/+</sup>* (Fig 2A and 2B). Left ventricular mass was not changed with *Htr2b*




**Fig 2. Genetic ablation of 5-HT<sub>2B</sub> results in a valve-specific hemodynamic improvement.** Sequential reduction of *Htr2b* expression from *Notch1*<sup>+/+</sup> mice results in a corresponding reduction in **A.** peak systolic velocity (mm/s) and **B.** mean pressure gradient (mmHg) across the AV at 6 months of age. Left ventricular structure and function were assessed by measurements of **C.** mass (mg) and **D.** ejection fraction (%), respectively. Neither metric was altered in *Htr2b* mutants indicating a primarily valvular phenotype. Sample sizes for all groups labeled in white in panel **A.** Mean $\pm$ SE, \* $p$ <0.05, 1-way ANOVA with post-hoc Tukey test for multiple comparisons.

<https://doi.org/10.1371/journal.pone.0238407.g002>

ablation (**Fig 2C**). Additionally, the function of the left ventricle was not altered based on ejection fraction measurements (**Fig 2D**). Together, this suggests the observed changes in hemodynamics are intrinsic to the AV and not due to altered cardiac function.

### 5-HT<sub>2B</sub> antagonism does not affect hemodynamic metrics of aortic valve disease

Based on results from the mutant study, we aimed to determine if the beneficial effects of *Htr2b* ablation on CAVD progression could be recapitulated using a pharmacological inhibitor specific to the 5-HT<sub>2B</sub> receptor. Following the initiation of SB204741 treatment (after 6 weeks of high cholesterol diet), the absolute change in peak velocity, mean gradient, left ventricular mass, and ejection fraction was calculated from 4 to 6 months of age. There was no significant change in valve metrics of peak velocity or mean pressure gradient (**Fig 3A and 3B**). Further,



**Fig 3. Pharmacological inhibition of 5-HT<sub>2B</sub> by SB204741 does not improve AV hemodynamics between four and six months.** Change in **A.** peak velocity and **B.** mean gradient revealed no differences in AV hemodynamic metrics between four and six months for DMSO or SB204741 treated groups. **C.** Left ventricle mass increased slightly in drug treated mice, however this did not translate to a statistically significant change in **D.** ejection fraction between four and six months. Boxes extend from mean to 25 and 75 percentiles and whiskers to minimum and maximum values, \* $P < 0.05$ , (A, D) one sample T-test or (B, C) Wilcoxon signed-rank test.


<https://doi.org/10.1371/journal.pone.0238407.g003>

there was a slight increase in left ventricle mass but no significant change in ejection fraction (Fig 3C and 3D). Despite AV improvement following genetic ablation, 5-HT<sub>2B</sub> antagonism by SB204741 does not reduce CAVD progression in *Notch1*<sup>+/-</sup> mice. Both the *Htr2b*<sup>-/-</sup> and SB204741 models were assayed for compensatory expression of *Htr2a* as a potential mechanism of disease. *Htr2a* expression was non-significantly decreased with administration of SB204741 (S3 Fig).

### 5-HT<sub>2B</sub> genetic ablation or pharmacological inhibition does not significantly change leaflet microstructure

Masson's trichrome staining was used to analyze collagen abundance and thickness of AV leaflet cross sections (Fig 4A and 4D). There was wide variation, particularly across wild-type and DMSO samples, and despite trends toward decreased thickness and increased collagen density, we observed no statistically significant changes (Fig 4B and 4C, S2 Fig). Similarly, there were no detected differences in leaflet thickness or collagen density in drug treatment groups despite the same trends as observed in the genetic ablation study (Fig 4E and 4F).





**Fig 4. Neither 5-HT<sub>2B</sub> genetic ablation nor pharmacological inhibition induces changes in leaflet thickness or collagen density.** A. Masson's trichrome stain was used to distinguish valve area and collagen tissue in mutant mice. B. Mean leaflet thickness was determined by measuring total valve area normalized length along cusp and was not changed. C. Collagen area fraction was not significantly changed between groups. D. Masson's trichrome stain was used in drug and vehicle treated mice. E. Mean leaflet thickness was not changed between treatments. F. Collagen density was not significantly different between treatments. Mean  $\pm$  SE, \* $P < 0.05$ , (B, C) Kruskal-Wallis 1-way ANOVA with post-hoc Dunn's test, (E, F) Mann-Whitney U-test. Black bar = 200  $\mu$ m.


<https://doi.org/10.1371/journal.pone.0238407.g004>

### 5-HT<sub>2B</sub> genetic ablation or pharmacological inhibition does not significantly change myofibroblast activation or osteoblast-like phenotype induction

To determine if myofibroblast activation played a role in the difference observed in mutant AV hemodynamic phenotypes, immunofluorescent labeling of the  $\alpha$ SMA protein was performed (Fig 5A and 5B). Similarly, Runx2 was stained to determine if there was evidence of osteoblast-like phenotype shift in valve cells and Alizarin Red S staining was used to identify osteogenic calcification (Fig 6A and 6B). There was no significant difference in  $\alpha$ SMA and high sample-to-sample variance was observed, particularly in the *Notch1<sup>+/-</sup>; Htr2b<sup>+/-</sup>* group (Fig 5C). Analysis of Runx2 staining revealed a 50–60% positivity rate of all valve cells independent of genotype and treatment, but there was little to no evidence of widespread calcification based on the Alizarin Red S stain. No significant differences in Runx2 expression were observed between groups (Fig 6C). phospho-ERK1/2 staining showed high variability which may indicate a multimodal distribution, similar to  $\alpha$ SMA (S4 Fig). The only samples showing definitively positive phospho-ERK1/2 staining were in *Notch1<sup>+/-</sup>; Htr2b<sup>+/-</sup>* and DMSO groups.

### 5-HT<sub>2B</sub> genetic ablation or pharmacological inhibition does not significantly change fibrotic CAVD transcripts

To further investigate the molecular mechanisms leading to differing hemodynamic phenotypes in mutant mice, RT-qPCR was performed for several genes of interest. Levels of these transcripts were not significantly changed, further pointing to a myofibroblast independent mechanism (Fig 7A). *Ccn2*, the gene for the fibrotic marker connective tissue growth factor



**Fig 5. Neither 5-HT<sub>2B</sub> genetic ablation nor pharmacological inhibition show a difference in myofibroblast activation based on  $\alpha$ SMA positive valve area.** A. Fluorescent imaging was carried out on mutant mice in the far red and DAPI channels for  $\alpha$ SMA and nuclei imaging, respectively. B. Fluorescent imaging was carried out as described on vehicle and drug treated mice as described. C. Area positive for  $\alpha$ SMA stain was normalized to the total valve area calculated by DAPI masking. Mean $\pm$ SEM, \* $p < 0.05$  following Kruskal-Wallis 1-way ANOVA with Dunn's post-test. White bar = 200  $\mu$ m.

<https://doi.org/10.1371/journal.pone.0238407.g005>


(CTGF) showed an overall group difference ( $p < 0.05$ ; Kruskal-Wallis 1-way ANOVA) but no differences when accounting for multiple comparisons ( $p = 0.0655$  between *Notch1<sup>+/-</sup>; Htr2b<sup>+/-</sup>* and *Notch1<sup>+/-</sup>; Htr2b<sup>-/-</sup>*;  $p = 0.0826$  between *Notch1<sup>+/-</sup>; Htr2b<sup>+/-</sup>* and *Notch1<sup>+/-</sup>; Htr2b<sup>-/-</sup>*).

RT-qPCR was performed in order to potentially detect any early markers of disease that may be present before symptoms can be detected by imaging. No significant changes were detected in the typical fibrotic CAVD markers of *Acta2*, *Cdh11*, *Col1a1*, or *Ccn2* (Fig 7B).

## Discussion

CAVD is a significant health concern in aging populations of developed countries, which are shifting toward more sedentary lifestyles. While the pathophysiology of the disease is poorly understood, serotonin signaling is a relatively well characterized driver of valve disease. The aim of this study was to assess the possibility of slowing or treating CAVD by genetically deleting or pharmacologically inhibiting 5-HT<sub>2B</sub> in a high-cholesterol diet *Notch1<sup>+/-</sup>* mouse model. We found that genetic mutation of the 5-HT<sub>2B</sub> receptor—via *Htr2b* deletion—mitigates hemodynamic progression of aortic stenosis.


We began by testing echocardiographic outcomes of genetic and pharmacological blockade of 5-HT<sub>2B</sub>. Genetic knockdown of *Htr2b* improved echocardiographic metrics of aortic stenosis (Fig 2), but receptor blockade with SB204741 had no effect (Fig 3). This may indicate that pharmacological inhibition of 5-HT<sub>2B</sub> using SB204741 is insufficient in blocking receptor



**Fig 6. Neither 5-HT<sub>2B</sub> genetic ablation nor pharmacological inhibition show a difference in osteoblast-like phenotype or osteogenic calcification.** A. Fluorescent (left column) and Alizarin Red S (right column) brightfield imaging was carried out on mutant mice. B. Fluorescent (left column) and Alizarin Red S (right column) brightfield imaging was carried out on vehicle and drug treated mice as described. C. Nuclei greater than 50% positive for Runx2 stain were counted and normalized by total nuclei. Mean+/-SEM, \*p<0.05 following Kruskal-Wallis 1-way ANOVA with Dunn's post-test. White/black bar = 200 μm.

<https://doi.org/10.1371/journal.pone.0238407.g006>

action compared to complete genetic deletion. This is supported by the fact that *Notch1*<sup>+/-</sup>; *Htr2b*<sup>+/-</sup> mice saw only slight, non-significant improvement over *Notch1*<sup>+/-</sup>; *Htr2b*<sup>+/+</sup> mice. In other words, only complete *Htr2b* knockout mice had significant changes. A stronger hemodynamic phenotype tends to develop between 6 and 9 months of age when using HFD (unpublished observations). It is possible that the mice in our study were not aged long enough to see appreciable differences in CAVD phenotypes. The age-range in this study is comparable to



**Fig 7. *Htr2b* mutant and SB204741-treated mice do not have altered transcription of genes associated with fibrotic/myofibroblast driven CAVD.** A. RT-qPCR was used to assess the levels of mRNA transcripts of *Acta2*, *Cdh11*, *Col1a1*, and *Ccn2*. No significant differences were detected. B. Similar targets were interrogated in drug treatment groups. Similarly, there were no differences. Mean+/-SE, \*P<0.05 following Kruskal-Wallis 1-way ANOVA with Dunn's post-test.

<https://doi.org/10.1371/journal.pone.0238407.g007>

early adulthood in humans whereas CAVD generally does not become prevalent until advanced age.

On assaying leaflet morphology and collagen structure, we saw no significant changes in any group (Fig 4). This was expected in drug treatment studies as we saw no significant differences in hemodynamic profile; therefore, we expected the structure was likely unchanged. Trends in mutant mice may indicate reduced leaflet hypertrophy in mutants which could lead to improvements in the AV hemodynamic profile. However, variability in the studied groups—particularly *Notch1*<sup>+/-</sup>;*Htr2b*<sup>+/+</sup>—precludes a clear conclusion from being drawn. The lack of change in collagen density may indicate an alternate structural cause for differences in the systolic AV flow profile in mutant mice, such as accumulation of glycosaminoglycans, undetected by using the trichrome staining method [6, 8, 36].

We also assessed myofibroblast activation by  $\alpha$ SMA staining. Serotonin signaling through the 2B receptor has shown to play a role in the activation of quiescent VICs into activated myofibroblasts. These cells play a role in the fibrosis and calcification that lead to impaired blood flow found in CAVD. One of the integral parts of myofibroblast activation is the adoption of a contractile phenotype that is characterized by abundant stress fibers primarily composed of the protein  $\alpha$ SMA [7]. Yet again, we saw no significant changes (Fig 5). It is possible that the myofibroblast activation phenotype may be a bimodal distribution and if a longer time course was studied, more mice would develop the elevated  $\alpha$ SMA phenotype seen in one *Notch1*<sup>+/-</sup>;*Htr2b*<sup>+/+</sup> mouse. However, when combined with collagen deposition based on trichrome staining, it appears the myofibroblast-driven fibrotic phenotype is likely not the cause of the differing phenotype which may point to a difference in glycosaminoglycan structure, osteogenic calcification, or cellular inflammation [6, 36, 37]. ERK1/2, a signaling molecule downstream of 5-HT<sub>2B</sub> activation showed similar activation variability to  $\alpha$ SMA and may also be a multimodal distribution. *Notch1* is known to downregulate Runx2 mediated osteoblast-like phenotype in CAVD [21, 38]. Indeed, immunostaining in this study shows Runx2 expression is present in *Notch1*<sup>+/-</sup> mice with around 50% of resident cells positive for the protein. Our data show *Htr2b* ablation nor receptor inhibition alter Runx2 expression or osteogenic calcification, suggesting the hemodynamic phenotype observed in mutant mice is not based on canonical osteogenic signaling pathways (Fig 6). Immune cell recruitment plays a key role in other 5-HT<sub>2B</sub>-mediated fibrotic disease and has been shown to contribute to the *Notch1*<sup>+/-</sup> model of CAVD, suggesting it may be involved here [25, 30, 39]. This may also indicate a phenotype arising from cells other than myofibroblasts. For instance, valvular endothelial cells are involved in CAVD progression via nitric oxide signaling and endothelial-mesenchymal transition [40, 41]. These alternative cellular mechanisms have not been rigorously interrogated in the context of 5-HT<sub>2B</sub> associated CAVD and may be a fruitful avenue of investigation.

RT-qPCR studies (Fig 7) also reveal little about the causative mechanisms of the changes found in the hemodynamics of the mutants. Changes in myofibroblast markers *Acta2* and *Cdh11* were not changed in mutants or drug groups. *Col1a1* was also not altered in any group, as would be expected based on histology analysis. Finally, *Ccn2*, a marker of fibrotic remodeling, was different at a group level in mutants but after correcting for multiple comparisons we observed no differences. This was also true between drug treatment groups. In addition, we did not find compensatory expression of 5-HT<sub>2B</sub> receptor (S3 Fig). 5-HT<sub>2C</sub> receptor subtype has been shown to be undetectable in the cardiovascular system and was not studied [28].

Overall, our results indicate that double mutant mice exhibit an improved hemodynamic phenotype at six months of age compared to *Notch1*<sup>+/-</sup>;*Htr2b*<sup>+/+</sup> mice. However, pharmacologic inhibition of 5-HT<sub>2B</sub> by SB204741 did not affect the development of CAVD between four and six months of age. This may be due to antagonism of the receptor not being a sufficient intervention to slow progression of the disease. SB204741 is known to be a selective antagonist

of the 2B receptor subtype but has relatively low potency [28]. While we have had success using a  $1 \text{ mg kg}^{-1} \text{ d}^{-1}$  in previous studies in the cardiovascular system, studies using SB204741 in other diseases like chronic liver disease or pancreatic cancer require higher dosages of up to  $10 \text{ mg kg}^{-1} \text{ d}^{-1}$  [30, 42, 43]. Additionally, our window of intervention may have been too early as six months of age is still relatively early for the disease to present.

Separately, results from the genetic study suggest prophylactic 5-HT<sub>2B</sub> inhibition may be sufficient for attenuating CAVD initiation, but therapeutic inhibition is insufficient for slowing the progression of existing disease. Histological analysis revealed mutant and drug treated mice did not significantly vary in level of leaflet hypertrophy or collagen density. Rough measurements in trichrome stains of aortic valve annulus diameter show a slight increase in *Htr2b* mutant mice which may result in a larger outflow area leading to lower flow and pressure across the valve but we were unable to confirm this using *in vivo* echocardiography (inadequate resolution for reliable measurements). Due to the potential variability introduced in the fixation, sectioning, and staining process in valve morphology we can only speculate in this potential explanation but caution that further investigation is needed to confirm this phenotype. There was also no difference in a subset of markers associated with myofibroblast activation and fibrosis that are generally detected in CAVD. Indeed, at the transcript level, there was little difference in general markers of CAVD.

Findings from the current study highlight the involvement of 5-HT<sub>2B</sub> signaling on CAVD initiation and progression based on improved AV hemodynamics following *Htr2b* deletion. Future studies focused on the therapeutic potential of targeted 5-HT<sub>2B</sub> receptor blockers should include a longer time course (12–18 months) to study the impact on the later stages of CAVD where the hemodynamic, tissue, and molecular phenotypes should be stronger and interrogate the effect of 5-HT<sub>2B</sub> inhibition before and after disease onset. Additionally, unbiased transcriptomic and proteomic approaches, such as mRNA sequencing, can be used to identify potential pathways of interrogation that may have been missed using a targeted approach.

## Limitations

Due to prohibitive cost and logistical concerns of housing mice and providing specialized diet *ad libitum* we were only able to age mice to 6 months of age, limiting the development of CAVD and AS phenotypes which correlate strongly with advanced age. A relatively low dosage of SB204741 was used due to the long time course of treatment and previous studies from our lab having success with this dosage. Annulus diameter was unable to be verified on parasternal long-axis echoes due to insufficient resolution making measurement unreliable. Aortic valve anatomy is variable across coronal/frontal plane studied. While efforts to sample several regions were developed, this is a potentially confounding aspect of the analysis. Molecular interrogation of causative pathways was limited due to the small amount of high-quality mRNA and tissue sections that can be extracted from single mouse aortic roots.

## Conclusions

The results from this study provide evidence that *Htr2b* mutant mice may have more compliant leaflets allowing for unimpeded blood flow in the *Notch1*<sup>+/-</sup> model of CAVD. However, the molecular changes underlying this tissue-level difference are unclear. We also found that despite significant improvement following genetic deletion, 5-HT<sub>2B</sub> antagonism using SB204741 was unable to cause a significant hemodynamic or histological difference between four and six months of age. Future studies are needed to fully evaluate the therapeutic potential of targeting 5-HT<sub>2B</sub> signaling for the treatment and management of CAVD.

## Supporting information

**S1 Fig. Portion of mice with hemodynamic CAVD based on criteria from [33].** 1320 mm/s is the 95<sup>th</sup> percentile of peak velocity found in ref. [33]. Using this criteria, 33%, 25%, and 12.5% of wild-type, knockout heterozygous, and knockout null mice developed hemodynamic CAVD, respectively.

(DOCX)

**S2 Fig. High morphological variability in *Notch1*<sup>+/-</sup>;*Htr2b*<sup>+/+</sup> and DMSO groups.** Statistical comparison is difficult due to wide variability in tissue characteristics in **A.** wild-type and **B.** DMSO treatment groups.

(DOCX)

**S3 Fig. Genetic ablation or pharmacological inhibition did not result in compensation of other 5-HT receptor subtypes.** Randomly selected samples from wild-type, knockout, DMSO, and SB204741 groups were selected and RT-qPCR was performed on the *Htr2a* gene. Expression was very low and there was no significant change. Mean $\pm$ SE, \*P<0.05, Mann-Whitney U-test.

(DOCX)

**S4 Fig. High phospho-ERK1/2 stain variability in *Notch1*<sup>+/-</sup>;*Htr2b*<sup>+/+</sup> and DMSO groups.** Statistical comparison is difficult due to wide variability in tissue characteristics in **A.** wild-type and **B.** DMSO treatment groups.

(DOCX)

## Author Contributions

**Conceptualization:** Cynthia R. Clark, W. David Merryman.

**Data curation:** J. Ethan Joll, II, Cynthia R. Clark, Christine S. Peters, Michael A. Raddatz.

**Formal analysis:** J. Ethan Joll, II, Cynthia R. Clark, Michael A. Raddatz, Matthew R. Bersi.

**Funding acquisition:** W. David Merryman.

**Investigation:** J. Ethan Joll, II, Christine S. Peters, Matthew R. Bersi.

**Methodology:** J. Ethan Joll, II, Cynthia R. Clark, Christine S. Peters, Matthew R. Bersi, W. David Merryman.

**Project administration:** W. David Merryman.

**Supervision:** W. David Merryman.

**Visualization:** Matthew R. Bersi.

**Writing – original draft:** J. Ethan Joll, II.

**Writing – review & editing:** Michael A. Raddatz, Matthew R. Bersi, W. David Merryman.

## References

1. Lindman BR, Clavel M-A, Mathieu P, Jung B, Lancellotti P, Otto CM, et al. Calcific aortic stenosis. *Nat Rev Dis Prim* [Internet]. 2016 Mar 3; 2:16006. Available from: <https://doi.org/10.1038/nrdp.2016.6> PMID: 27188578
2. Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. *Lancet* (London, England). 2006 Sep; 368(9540):1005–11. [https://doi.org/10.1016/S0140-6736\(06\)69208-8](https://doi.org/10.1016/S0140-6736(06)69208-8) PMID: 16980116

3. Osnabrugge RLJ, Mylotte D, Head SJ, Van Mieghem NM, Nkomo VT, LeReun CM, et al. Aortic Stenosis in the Elderly: Disease Prevalence and Number of Candidates for Transcatheter Aortic Valve Replacement: A Meta-Analysis and Modeling Study. *J Am Coll Cardiol* [Internet]. 2013; 62(11):1002–12. Available from: <http://www.sciencedirect.com/science/article/pii/S0735109713020792> <https://doi.org/10.1016/j.jacc.2013.05.015> PMID: 23727214
4. Otto CM, Burwash IG, Legget ME, Munt BI, Fujioka M, Healy NL, et al. Prospective study of asymptomatic valvular aortic stenosis: Clinical, echocardiographic, and exercise predictors of outcome. *Circulation*. 1997
5. VS S., Alvaro A, BE J., BM S., CC W., CA P., et al. Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association. *Circulation* [Internet]. 2020 Mar 3; 141(9):e139–596. Available from: <https://doi.org/10.1161/CIR.0000000000000757> PMID: 31992061
6. Rajamannan NM, Evans FJ, Aikawa E, Grande-Allen KJ, Demer LL, Heistad DD, et al. Calcific Aortic Valve Disease: Not Simply a Degenerative Process. *Circulation* [Internet]. 2011 Oct 17; 124(16):1783 LP– 1791. Available from: <http://circ.ahajournals.org/content/124/16/1783.abstract> <https://doi.org/10.1161/CIRCULATIONAHA.110.006767> PMID: 22007101
7. Bowler MA, Merryman WD. In vitro models of aortic valve calcification: Solidifying a system. Vol. 24, *Cardiovascular Pathology*. 2015. p. 1–10. <https://doi.org/10.1016/j.carpath.2014.08.003> PMID: 25249188
8. Rajamannan NM, Subramaniam M, Rickard D, Stock SR, Donovan J, Springett M, et al. Human aortic valve calcification is associated with an osteoblast phenotype. *Circulation*. 2003; 107(17):2181–4. <https://doi.org/10.1161/01.CIR.0000070591.21548.69> PMID: 12719282
9. Iung B, Cachier A, Baron G, Messika-Zeitoun D, Delahaye F, Tornos P, et al. Decision-making in elderly patients with severe aortic stenosis: why are so many denied surgery? *Eur Heart J* [Internet]. 2005 Sep 1; 26(24):2714–20. Available from: <https://doi.org/10.1093/eurheartj/ehi471> PMID: 16141261
10. Druce M, Rockall A, Grossman AB. Fibrosis and carcinoid syndrome: from causation to future therapy. *Nat Rev Endocrinol* [Internet]. 2009; 5(5):276–83. Available from: <https://doi.org/10.1038/nrendo.2009.51> PMID: 19444261
11. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, et al. Valvular Heart Disease Associated with Fenfluramine–Phentermine. *N Engl J Med* [Internet]. 1997 Aug 28; 337(9):581–8. Available from: <https://doi.org/10.1056/NEJM199708283370901> PMID: 9271479
12. Fitzgerald LW, Burn TC, Brown BS, Patterson JP, Corjay MH, Valentine PA, et al. Possible Role of Valvular Serotonin 5-HT<sub>2B</sub> Receptors in the Cardiopathy Associated with Fenfluramine. *Mol Pharmacol* [Internet]. 2000 Jan 1; 57(1):75 LP– 81. Available from: <http://molpharm.aspetjournals.org/content/57/1/75.abstract>
13. RR B., BM H., SJ E., Laura R, Ace M, HS J., et al. Evidence for Possible Involvement of 5-HT<sub>2B</sub> Receptors in the Cardiac Valvulopathy Associated With Fenfluramine and Other Serotonergic Medications. *Circulation* [Internet]. 2000 Dec 5; 102(23):2836–41. Available from: <https://doi.org/10.1161/01.cir.102.23.2836> PMID: 11104741
14. Elangbam CS, Job LE, Zadrozny LM, Barton JC, Yoon LW, Gates LD, et al. 5-Hydroxytryptamine (5HT)-induced valvulopathy: Compositional valvular alterations are associated with 5HT<sub>2B</sub> receptor and 5HT transporter transcript changes in Sprague-Dawley rats. *Exp Toxicol Pathol* [Internet]. 2008; 60(4):253–62. Available from: <http://www.sciencedirect.com/science/article/pii/S0940299308000523> <https://doi.org/10.1016/j.etp.2008.03.005> PMID: 18511249
15. NC G., Pierre H, Nadia M, Jean-Luc V, DM P., Laurent M, et al. Ablation of Serotonin 5-HT<sub>2B</sub> Receptors in Mice Leads to Abnormal Cardiac Structure and Function. *Circulation* [Internet]. 2001 Jun 19; 103(24):2973–9. Available from: <https://doi.org/10.1161/01.cir.103.24.2973> PMID: 11413089
16. Fabrice J, Jacques C, Alexandre S, Nelly E, NC G., L Jean-Marie, et al. Involvement of the Serotonin 5-HT<sub>2B</sub> Receptor in Cardiac Hypertrophy Linked to Sympathetic Stimulation. *Circulation* [Internet]. 2004 Aug 24; 110(8):969–74. Available from: <https://doi.org/10.1161/01.CIR.0000139856.20505.57> PMID: 15302781
17. Laurent M, Marc-André L, Fabrice J, Pascal B, Luc M, Jacques de C. Serotonin 5-HT<sub>2B</sub> Receptor Blockade Prevents Reactive Oxygen Species-Induced Cardiac Hypertrophy in Mice. *Hypertension* [Internet]. 2008 Aug 1; 52(2):301–7. Available from: <https://doi.org/10.1161/HYPERTENSIONAHA.107.105551> PMID: 18591460
18. Cremer SE, Moesgaard SG, Rasmussen CE, Zois NE, Falk T, Reimann MJ, et al. Alpha-smooth muscle actin and serotonin receptors 2A and 2B in dogs with myxomatous mitral valve disease. *Res Vet Sci* [Internet]. 2015; 100:197–206. Available from: <http://www.sciencedirect.com/science/article/pii/S0034528815000946> <https://doi.org/10.1016/j.rvsc.2015.03.020> PMID: 25843893

19. Ayme-Dietrich E, Lawson R, Côté F, de Tapia C, Da Silva S, Ebel C, et al. The role of 5-HT<sub>2B</sub> receptors in mitral valvulopathy: bone marrow mobilization of endothelial progenitors. *Br J Pharmacol* [Internet]. 2017 Nov 1; 174(22):4123–39. Available from: <https://doi.org/10.1111/bph.13981> PMID: 28806488
20. Hutcheson JD, Ryzhova LM, Setola V, Merryman WD. 5-HT<sub>2B</sub> antagonism arrests non-canonical TGF- $\beta$ 1-induced valvular myofibroblast differentiation. *J Mol Cell Cardiol* [Internet]. 2012; 53(5):707–14. Available from: <http://www.sciencedirect.com/science/article/pii/S002228281200301X> <https://doi.org/10.1016/j.jmcc.2012.08.012> PMID: 22940605
21. Garg V, Muth AN, Ransom JF, Schluterman MK, Barnes R, King IN, et al. Mutations in NOTCH1 cause aortic valve disease. *Nature*. 2005; 437(7056):270–4. <https://doi.org/10.1038/nature03940> PMID: 16025100
22. Meritxell N, Donal M, Beatriz M-P, Yolanda B, CJ C., Francisco F-A, et al. Diet-Induced Aortic Valve Disease in Mice Haploinsufficient for the Notch Pathway Effector RBPJK/CSL. *Arterioscler Thromb Vasc Biol* [Internet]. 2011 Jul 1; 31(7):1580–8. Available from: <https://doi.org/10.1161/ATVBAHA.111.227561> PMID: 21493891
23. Chen J, Ryzhova LM, Sewell-Loftin MK, Brown CB, Huppert SS, Baldwin HS, et al. Notch1 mutation leads to valvular calcification through enhanced myofibroblast mechanotransduction. *Arterioscler Thromb Vasc Biol*. 2015; 35(7):1597–605. <https://doi.org/10.1161/ATVBAHA.114.305095> PMID: 26023079
24. CC R., BM A., Caleb SJ, David MW. Targeting Cadherin-11 Prevents Notch1-Mediated Calcific Aortic Valve Disease. *Circulation* [Internet]. 2017 Jun 13; 135(24):2448–50. Available from: <https://doi.org/10.1161/CIRCULATIONAHA.117.027771> PMID: 28606953
25. Raddatz MA, Huffstater TM, Bersi MR, Reinfeld BI, Madden MZ, Booton SE, et al. Macrophages Promote Aortic Valve Cell Calcification and Alter STAT3 (Signal Transducer and Activator of Transcription 3) Splicing. *Arterioscler Thromb Vasc Biol*. 2020 Apr;2020.01.24.919001.
26. Conlon RA, Reaume AG, Rossant J. Notch1 is required for the coordinate segmentation of somites. *Development* [Internet]. 1995 May 1; 121(5):1533 LP– 1545. Available from: <http://dev.biologists.org/content/121/5/1533.abstract> PMID: 7789282
27. Nebigil CG, Choi D-S, Dierich A, Hickel P, Le Meur M, Messaddeq N, et al. Serotonin 2B receptor is required for heart development. *Proc Natl Acad Sci* [Internet]. 2000 Aug 15; 97(17):9508 LP– 9513. Available from: <http://www.pnas.org/content/97/17/9508.abstract> <https://doi.org/10.1073/pnas.97.17.9508> PMID: 10944220
28. Maroteaux L, Ayme-Dietrich E, Aubertin-Kirch G, Banas S, Quentin E, Lawson R, et al. New therapeutic opportunities for 5-HT<sub>2</sub> receptor ligands. *Pharmacol Ther* [Internet]. 2017; 170:14–36. Available from: <http://www.sciencedirect.com/science/article/pii/S0163725816301875> <https://doi.org/10.1016/j.pharmthera.2016.10.008> PMID: 27771435
29. Forbes IT, Jones GE, Murphy OE, Holland V, Baxter GS. N-(1-Methyl-5-indolyl)-N'-(3-methyl-5-isothiazolyl)urea: A Novel, High-Affinity 5-HT<sub>2B</sub> Receptor Antagonist. *J Med Chem*. 1995; 38(6):855–7. <https://doi.org/10.1021/jm00006a001> PMID: 7699699
30. Bloodworth NC. Bone-Marrow Derived Proangiogenic Cells Mediate Pulmonary Arteriole Stiffening via Serotonin 2B Receptor Dependent Mechanism. *Circ Res*. 2017; 738:1–45.
31. Ferruzzi J, Di Achille P, Tellides G, Humphrey JD. Combining in vivo and in vitro biomechanical data reveals key roles of perivascular tethering in central artery function. *PLoS One* [Internet]. 2018 Sep 7; 13(9):e0201379. Available from: <https://doi.org/10.1371/journal.pone.0201379> PMID: 30192758
32. Schroer AK, Bersi MR, Clark CR, Zhang Q, Sanders LH, Hatzopoulos AK, et al. Cadherin-11 blockade reduces inflammation-driven fibrotic remodeling and improves outcomes after myocardial infarction. *JCI Insight* [Internet]. 2019 Sep 19; 4(18). Available from: <https://doi.org/10.1172/jci.insight.131545>
33. Bersi MR, Khosravi R, Wujciak AJ, Harrison DG, Humphrey JD. Differential cell-matrix mechanoadaptations and inflammation drive regional propensities to aortic fibrosis, aneurysm or dissection in hypertension. *J R Soc Interface* [Internet]. 2017 Nov 30; 14(136):20170327. Available from: <https://doi.org/10.1098/rsif.2017.0327> PMID: 29118111
34. Wienert S, Heim D, Saeger K, Stenzinger A, Beil M, Hufnagl P, et al. Detection and Segmentation of Cell Nuclei in Virtual Microscopy Images: A Minimum-Model Approach. *Sci Rep* [Internet]. 2012; 2(1):503. Available from: <https://doi.org/10.1038/srep00503> PMID: 22787560
35. Annabi M-S, Clisson M, Fleury M-A, Voisine M, Hervault M, Shen M, et al. Sex-differences in echocardiographic assessment of aortic valve in young adult LDLr<sup>-/-</sup>/ApoB100/100/IGF-II<sup>+/-</sup> mice. *Exp Gerontol* [Internet]. 2020; 140:111075. Available from: <http://www.sciencedirect.com/science/article/pii/S053155652030423X> <https://doi.org/10.1016/j.exger.2020.111075> PMID: 32861845
36. Grande-Allen KJ, Osman N, Ballinger ML, Dadlani H, Marasco S, Little PJ. Glycosaminoglycan synthesis and structure as targets for the prevention of calcific aortic valve disease. *Cardiovasc Res* [Internet].



- 2007 Oct 1; 76(1):19–28. Available from: <https://doi.org/10.1016/j.cardiores.2007.05.014> PMID: 17560967
37. Raddatz MA, Madhur MS, Merryman WD. Adaptive immune cells in calcific aortic valve disease. *Am J Physiol Circ Physiol*. 2019 Jul; 317(1):H141–55. <https://doi.org/10.1152/ajpheart.00100.2019> PMID: 31050556
  38. Nigam V, Srivastava D. Notch1 represses osteogenic pathways in aortic valve cells. *J Mol Cell Cardiol* [Internet]. 2009; 47(6):828–34. Available from: <http://www.sciencedirect.com/science/article/pii/S0022282809003290> <https://doi.org/10.1016/j.yjmcc.2009.08.008> PMID: 19695258
  39. Launay J-M, Hervé P, Callebort J, Mallat Z, Collet C, Doly S, et al. Serotonin 5-HT<sub>2B</sub> receptors are required for bone-marrow contribution to pulmonary arterial hypertension. *Blood*. 2012; 119(7):1772–80. <https://doi.org/10.1182/blood-2011-06-358374> PMID: 22186990
  40. Bosse K, Hans CP, Zhao N, Koenig SN, Huang N, Guggilam A, et al. Endothelial nitric oxide signaling regulates Notch1 in aortic valve disease. *J Mol Cell Cardiol* [Internet]. 2013; 60:27–35. Available from: <http://www.sciencedirect.com/science/article/pii/S0022282813001272> <https://doi.org/10.1016/j.yjmcc.2013.04.001> PMID: 23583836
  41. Paranya G, Vineberg S, Dvorin S, Kaushal S, Roth SJ, Rabkin E, et al. Aortic valve endothelial cells undergo transforming growth factor- $\beta$ -mediated and non-transforming growth factor- $\beta$ -mediated trans-differentiation in Vitro. *Am J Pathol*. 2001 [https://doi.org/10.1016/s0002-9440\(10\)62520-5](https://doi.org/10.1016/s0002-9440(10)62520-5) PMID: 11583961
  42. Ebrahimkhani MR, Oakley F, Murphy LB, Mann J, Moles A, Perugorria MJ, et al. Stimulating healthy tissue regeneration by targeting the 5-HT<sub>2B</sub> receptor in chronic liver disease. *Nat Med* [Internet]. 2011; 17(12):1668–73. Available from: <https://doi.org/10.1038/nm.2490> PMID: 22120177
  43. Jiang S-H, Li J, Dong F-Y, Yang J-Y, Liu D-J, Yang X-M, et al. Increased Serotonin Signaling Contributes to the Warburg Effect in Pancreatic Tumor Cells Under Metabolic Stress and Promotes Growth of Pancreatic Tumors in Mice. *Gastroenterology* [Internet]. 2017; 153(1):277–291.e19. Available from: <http://www.sciencedirect.com/science/article/pii/S0016508517302718> <https://doi.org/10.1053/j.gastro.2017.03.008> PMID: 28315323